The stock is trading at $29.05 which is just over $27.39, the stock’s 50 day moving average and marginally over the 200 day moving average of $27.39. The 50 day moving average moved up $1.66 whereas the 200 day moving average was up $1.66 or +6.08%. (NASDAQ:RGNX) shares saw heavy trading volume with 331K shares changing hands by the end of trading on Wednesday. Trading volume was up 107.32% over the stocks average daily volume.
Investors are more bearish of late at least if you consider the motion in short interest. The firm recorded a rise in short interest between August 15, 2017 and August 31, 2017 of 10.84%. Short shares increased from 1,325,196 to 1,468,875 over that timeframe. Days to cover decreased 0.0 to 6.0 and the percentage of shorted shares is 0.05% as of August 31.
REGENXBIO Inc. (NASDAQ:RGNX) has been the object of insider selling activity recently. Chief Medical Officer Stephen Yoo sold 27,342 shares at an average price of $25.00 on September 8th. That brings the Chief Medical Officer’s holdings to $0 as reported to the SEC. Chief Medical Officer Stephen Yoo disclosed the sale of 15,000 shares. The shares were sold on August 21st for an average price of $20.03. The Chief Medical Officer now owns $0 of the stock according to the SEC filing.
Kenneth T. Mills, President and CEO disclosed the sale of 6,500 shares of RGNX stock. The shares were purchased at an average price of $20.05. Mills now owns $2,115,275 of the stock per the Form 4 SEC filing.
Additionally, here are a few investment firms who have increased or decreased their stake in (RGNX). As of the end of the quarter Point72 Asset Management, L.p. had bought 290,186 shares growing its stake by 1,240.1%. The value of the company’s investment in REGENXBIO Inc. increased from $452,000 to $6,193,000 a change of 1,270.1% quarter to quarter. As of quarter end Schonfeld Strategic Advisors LLC had disposed of a total of 1,911 shares trimming its position 2.5%. The value of the investment in REGENXBIO Inc. went from $1,485,000 to $1,481,000 a change of $4,000 since the last quarter.
As of the end of the quarter Graticule Asia Macro Advisors LLC had sold 24,470 shares trimming its holdings by 49.8%. The value of the total investment in REGENXBIO Inc. went from $949,000 to $487,000 decreasing 48.7% quarter over quarter. As of quarter end Ubs Group Ag had acquired a total of 5,222 shares growing its stake by 497.3%. The value in dollars went from $20,000 to $124,000 increasing 520.0% for the reporting period.
Equity analyst Evercore ISI Group began coverage of RGNX setting a rating of “Outperform”.
As of the last earnings report the EPS was $-2.69 and is projected to be $-2.87 for the current year with 30,894,000 shares currently outstanding. Analysts expect next quarter’s EPS will be $-0.80 with next year’s EPS anticipated to be $-3.10.
REGENXBIO Inc., launched on July 16, 2008, is a clinical-stage biotechnology company. The Business’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively..